Michael Benatar. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Adjuvants, Immunologic/administration & dosageAdjuvants, Immunologic/therapeutic useClinical Trials, Phase III as TopicDrug Administration ScheduleHumansInterferon beta-1aInterferon beta-1bInterferon-beta/administration & dosageInterferon-beta/therapeutic useMultiple Sclerosis/drug therapyTime FactorsTreatment Outcome
Substances: See more » Adjuvants, ImmunologicInterferon beta-1bInterferon-betaInterferon beta-1a
Year: 2002 PMID: 12424021 DOI: 10.1016/S0140-6736(02)11385-7
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321